Phase II study of perioperative chemotherapy (preoperative XELOX+Bevacizumab/ postoperative XELOX) in patients with locally advanced rectal cancer
- Conditions
- Rectal cancer
- Registration Number
- JPRN-UMIN000013000
- Lead Sponsor
- Sano Hospital Masahito Kotaka, MD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Not provided
1. Need to drain malignant coelomic fluid; 2.Multiple primary cancer within 5years 3. Bleeding tendency, coagulation factor or abnormal clotting disorder (INR 1.5) 4. Intestinal paralysis, intestinal obstruction, peptic ulcer uncontrollable 5.Serious complications (diabetes, infections, diarrhea) 6. Symptomatic or asymptomatic but treated heart disease. History of those within one year prior to enrollment 7. History of the serious hypersensitivity for fluorouracil, platinum compound. History of adverse events related to DPD loss 8. Peripheral sensory neuropathy (CTCAE v4.0 Grade 1); 9.Pulmonary fibrosis or interstitial pneumonia 10. Current or previous (within the last 1 year) history of cerebrovascular disease 11.Administered antithrombotic agents for thrombosis within 10 days prior to enrollment 12. Serious hypertension 13. History of gastrointestinal perforation 14.Pregnant women,possibly pregnant women, wishing to become pregnant, and nursing mothers; 15.No intention to practice birth control; 16.Previously treated with oxaliplatin;or capecitabine 17.Any other medical conditions disable to comply with the protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method